Detection of antiphospholipid antibodies (aPL) are central to the definition of the antiphospholipid (antibody) syndrome (APS). Thrombosis in certain vascular beds, such as the cerebral circulation, the veins of the lower legs and cutaneous vessels, and/or fetal loss, are common manifestations of APS. However, aPL have been found in association with a large range of other clinical conditions-these conditions constitute a rather heterogeneous group and are the subject of this review. Thus, aPL may rarely be found in association with thromboses of vascular beds other than those commonly associated with APS. The combination of thrombosis and aPL still satisfies the criteria for APS, and management of this group of patients is the same as that of APS associated with the more common manifestations of the disease. Alternatively, aPL may be detected in a range of conditions where thrombosis cannot be clearly demonstrated, such as duodenal ulcer or transverse myelopathy. The approach to management of patients who have aPL in association with these conditions is less clear, although in some cases interventions to remove the associated antibody have been associated with amelioration of the condition. Finally, in several studies, aPL have been detected in a proportion of patients with conditions occurring commonly in the normal population-these findings have to be treated with caution in view of inconsistent findings between the reported results and methodological limitation of studies purporting to show positive results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0032-1311992 | DOI Listing |
Rheumatol Adv Pract
January 2025
Department of Internal Medicine, Hospital General "Dr. Manuel Gea González", Ciudad de Mexico, Mexico.
APS is an autoimmune disorder characterized by thrombosis and pregnancy complications, primarily driven by aPLs such as LA, aCL and anti-β2 glycoprotein I (a-β2GPI). Despite advances in anticoagulation therapies, managing refractory APS cases remains challenging. Emerging therapies, including rituximab, eculizumab and HCQ, show potential in addressing the underlying mechanisms of APS.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Department of Nephrology and Dialysis, Brugmann University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Background: The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis. AVF stenosis is a common complication, often requiring balloon angioplasty. For recurrent stenosis, AVF stenting may be an option.
View Article and Find Full Text PDFEur J Intern Med
January 2025
Hospital das Clínicas da University of São Paulo Medical School (HCFMUSP), Brazil; Department of Pathology, Faculty of Medical Sciences of the University of Campinas (UNICAMP), Brazil.
Egypt J Immunol
January 2025
Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
The coronavirus disease 2019 (COVID-19) pandemic had significant global health impact. Like systemic autoimmune diseases, COVID-19 may manifest with systemic and heterogenous clinical presentations. This study aimed to evaluate the prevalence of autoimmune rheumatic manifestations among a cohort of Egyptian patients with COVID-19 infection.
View Article and Find Full Text PDFCureus
December 2024
Urogynecology, Advanced Center for Urogynecology Private Limited, Chennai, IND.
Background Obesity is postulated to be a high-risk factor for thrombosis along with the inherent hypercoagulability of pregnancy. The Confidential Review of Maternal Deaths (CRMD) found that thrombosis was one of the major causes of maternal deaths in Kerala. This study investigates the major risk factor - obesity and its association with thrombosis in our study setting, along with other risk factors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!